224 related articles for article (PubMed ID: 22575017)
1. Antitumor agent calixarene 0118 targets human galectin-1 as an allosteric inhibitor of carbohydrate binding.
Dings RP; Miller MC; Nesmelova I; Astorgues-Xerri L; Kumar N; Serova M; Chen X; Raymond E; Hoye TR; Mayo KH
J Med Chem; 2012 Jun; 55(11):5121-9. PubMed ID: 22575017
[TBL] [Abstract][Full Text] [Related]
2. Structure-based optimization of angiostatic agent 6DBF7, an allosteric antagonist of galectin-1.
Dings RP; Kumar N; Miller MC; Loren M; Rangwala H; Hoye TR; Mayo KH
J Pharmacol Exp Ther; 2013 Mar; 344(3):589-99. PubMed ID: 23232447
[TBL] [Abstract][Full Text] [Related]
3. Targeting the CRD F-face of Human Galectin-3 and Allosterically Modulating Glycan Binding by Angiostatic PTX008 and a Structurally Optimized Derivative.
Miller MC; Zheng Y; Suylen D; Ippel H; Cañada FJ; Berbís MA; Jiménez-Barbero J; Tai G; Gabius HJ; Mayo KH
ChemMedChem; 2021 Feb; 16(4):713-723. PubMed ID: 33156953
[TBL] [Abstract][Full Text] [Related]
4. Treatment of B-cell precursor acute lymphoblastic leukemia with the Galectin-1 inhibitor PTX008.
Paz H; Joo EJ; Chou CH; Fei F; Mayo KH; Abdel-Azim H; Ghazarian H; Groffen J; Heisterkamp N
J Exp Clin Cancer Res; 2018 Mar; 37(1):67. PubMed ID: 29580262
[TBL] [Abstract][Full Text] [Related]
5. New Treatment Strategy Targeting Galectin-1 against Thyroid Cancer.
Gheysen L; Soumoy L; Trelcat A; Verset L; Journe F; Saussez S
Cells; 2021 May; 10(5):. PubMed ID: 34063063
[TBL] [Abstract][Full Text] [Related]
6. OTX008, a selective small-molecule inhibitor of galectin-1, downregulates cancer cell proliferation, invasion and tumour angiogenesis.
Astorgues-Xerri L; Riveiro ME; Tijeras-Raballand A; Serova M; Rabinovich GA; Bieche I; Vidaud M; de Gramont A; Martinet M; Cvitkovic E; Faivre S; Raymond E
Eur J Cancer; 2014 Sep; 50(14):2463-77. PubMed ID: 25042151
[TBL] [Abstract][Full Text] [Related]
7. Unraveling galectin-1 as a novel therapeutic target for cancer.
Astorgues-Xerri L; Riveiro ME; Tijeras-Raballand A; Serova M; Neuzillet C; Albert S; Raymond E; Faivre S
Cancer Treat Rev; 2014 Mar; 40(2):307-19. PubMed ID: 23953240
[TBL] [Abstract][Full Text] [Related]
8. The luteotrophic function of galectin-1 by binding to the glycans on vascular endothelial growth factor receptor-2 in bovine luteal cells.
Sano M; Hashiba K; Nio-Kobayashi J; Okuda K
J Reprod Dev; 2015; 61(5):439-48. PubMed ID: 26155753
[TBL] [Abstract][Full Text] [Related]
9. Galectin-1 Inhibitor OTX008 Induces Tumor Vessel Normalization and Tumor Growth Inhibition in Human Head and Neck Squamous Cell Carcinoma Models.
Koonce NA; Griffin RJ; Dings RPM
Int J Mol Sci; 2017 Dec; 18(12):. PubMed ID: 29232825
[TBL] [Abstract][Full Text] [Related]
10. A key role for galectin-1 in sprouting angiogenesis revealed by novel rationally designed antibodies.
van Beijnum JR; Thijssen VL; Läppchen T; Wong TJ; Verel I; Engbersen M; Schulkens IA; Rossin R; Grüll H; Griffioen AW; Nowak-Sliwinska P
Int J Cancer; 2016 Aug; 139(4):824-35. PubMed ID: 27062254
[TBL] [Abstract][Full Text] [Related]
11. The carbohydrate-binding domain on galectin-1 is more extensive for a complex glycan than for simple saccharides: implications for galectin-glycan interactions at the cell surface.
Miller MC; Nesmelova IV; Platt D; Klyosov A; Mayo KH
Biochem J; 2009 Jun; 421(2):211-21. PubMed ID: 19432560
[TBL] [Abstract][Full Text] [Related]
12. Galectin-1 is essential in tumor angiogenesis and is a target for antiangiogenesis therapy.
Thijssen VL; Postel R; Brandwijk RJ; Dings RP; Nesmelova I; Satijn S; Verhofstad N; Nakabeppu Y; Baum LG; Bakkers J; Mayo KH; Poirier F; Griffioen AW
Proc Natl Acad Sci U S A; 2006 Oct; 103(43):15975-80. PubMed ID: 17043243
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and antineoplastic activity of galectin-1-targeting OTX008 in combination with sunitinib.
Zucchetti M; Bonezzi K; Frapolli R; Sala F; Borsotti P; Zangarini M; Cvitkovic E; Noel K; Ubezio P; Giavazzi R; D'Incalci M; Taraboletti G
Cancer Chemother Pharmacol; 2013 Oct; 72(4):879-87. PubMed ID: 23978989
[TBL] [Abstract][Full Text] [Related]
14. Novel benzimidazole-triazole hybrids as apoptosis inducing agents in lung cancer: Design, synthesis,
Sridhar Goud N; Pooladanda V; Muni Chandra K; Lakshmi Soukya PS; Alvala R; Kumar P; Nagaraj C; Dawn Bharath R; Qureshi IA; Godugu C; Alvala M
Bioorg Chem; 2020 Sep; 102():104125. PubMed ID: 32738568
[TBL] [Abstract][Full Text] [Related]
15. Polycationic calixarene PTX013, a potent cytotoxic agent against tumors and drug resistant cancer.
Dings RP; Levine JI; Brown SG; Astorgues-Xerri L; MacDonald JR; Hoye TR; Raymond E; Mayo KH
Invest New Drugs; 2013 Oct; 31(5):1142-50. PubMed ID: 23392775
[TBL] [Abstract][Full Text] [Related]
16. How altering the modular architecture affects aspects of lectin activity: case study on human galectin-1.
Kutzner TJ; Gabba A; FitzGerald FG; Shilova NV; García Caballero G; Ludwig AK; Manning JC; Knospe C; Kaltner H; Sinowatz F; Murphy PV; Cudic M; Bovin NV; Gabius HJ
Glycobiology; 2019 Jul; 29(8):593-607. PubMed ID: 31091305
[TBL] [Abstract][Full Text] [Related]
17. Galectin-1 inhibition induces cell apoptosis through dual suppression of CXCR4 and Ras pathways in human malignant peripheral nerve sheath tumors.
Shih TC; Fan Y; Kiss S; Li X; Deng XN; Liu R; Chen XJ; Carney R; Chen A; Ghosh PM; Lam KS
Neuro Oncol; 2019 Nov; 21(11):1389-1400. PubMed ID: 31127849
[TBL] [Abstract][Full Text] [Related]
18. Negative regulation of RPE cell attachment by carbohydrate-dependent cell surface binding of galectin-3 and inhibition of the ERK-MAPK pathway.
Alge-Priglinger CS; André S; Schoeffl H; Kampik A; Strauss RW; Kernt M; Gabius HJ; Priglinger SG
Biochimie; 2011 Mar; 93(3):477-88. PubMed ID: 21094672
[TBL] [Abstract][Full Text] [Related]
19. Inhibiting tumor growth by targeting tumor vasculature with galectin-1 antagonist anginex conjugated to the cytotoxic acylfulvene, 6-hydroxylpropylacylfulvene.
Dings RP; Van Laar ES; Loren M; Webber J; Zhang Y; Waters SJ; Macdonald JR; Mayo KH
Bioconjug Chem; 2010 Jan; 21(1):20-7. PubMed ID: 20020769
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis and evaluation of calix[4]arene-based carbonyl amide derivatives with antitumor activities.
An L; Wang C; Zheng YG; Liu JD; Huang TH
Eur J Med Chem; 2021 Jan; 210():112984. PubMed ID: 33183867
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
